At Cumberland, we’re always seeking opportunities to maximize the potential of our existing brands, develop new ways to use our products, expand our roster of distinguished partners and acquire select new brands. We're pleased to share several notable developments on this front from the first quarter of 2022:

  • Our acquisition of Sancuso® – an FDA-approved dissolvable prescription patch to prevent nausea and vomiting in patients undergoing certain chemotherapy treatments – from the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd.


  • The formation of a new sales division, Cumberland Oncology, consisting of a group of seven individuals who supported the brand  Sancuso at Kyowa.


  • A Co-promotion agreement with Verity Pharmaceuticals, which will promote Sancuso throughout most of the U.S. through its national oncology sales organization.


  • Continued enrollment in our clinical programs after having been interrupted by the pandemic. With a series of Phase II clinical studies underway, we are continuing to evaluate our ifetroban candidate in patients with a series of unmet medical needs.

Also during the first quarter, we shared several developments regarding Vibativ®, our antibiotic used to treat patients with pneumonia and serious skin infections resulting from gram positive bacteria:

  • We announced the launch of Vibativ in Puerto Rico, through a partnership with Verity Pharmaceuticals.


I’d like to extend a big thank you to our team at Cumberland for their continued support of our mission to provide high-quality medical care to patients throughout the world. We’re particularly encouraged by our acquisition of Sancuso and our new national co-promotion partnership with Verity Pharmaceuticals. With the contributions from the new product, we expect to deliver double-digit revenue growth this year while continuing to generate positive cashflow from operations.

We look forward to sharing more updates with you throughout the year.